secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-138893
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre licenses Paragon’s α4ß7 and TL1A antibodies, appoints Dr. Milligan to board, and approves Series B conversion
--------------------------------------------------------------------------------

- Entered exclusive license with Paragon for α4ß7 and TL1A antibodies; up to $22M milestones per program plus low single-digit royalties.
- Appointed Dr. Sandra Milligan (former Merck, Genentech, Amgen executive) to Board of Directors, effective May 14, 2024.
- Stockholders approved issuance of common upon conversion of Series B Preferred (Dec 2023 and Mar 2024 tranches).
- Pro forma shares outstanding expected ~65.2M after full conversion of Series B and Series A Preferred.
- Certificate of Amendment extended officer exculpation provisions in charter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524138893/0001193125-24-138893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524138893/d839821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer